For the quarter ending 2025-09-30, CODX had $328,762 increase in cash & cash equivalents over the period. -$5,979,690 in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -5,886,823 | -15,263,388 |
| Depreciation and amortization | 267,383 | 571,859 |
| Stock-based compensation expense | 500,585 | 1,455,493 |
| Common stock issued for financial advisory services | 0 | 135,000 |
| Change in fair value of acquisition contingencies | -42,345 | 727,289 |
| Non-cash lease expense | -2,982 | -2,003 |
| Realized gain on investments | 41,542 | 641,823 |
| Loss from equity method investment | -55,959 | -15,204 |
| (gain) loss on disposition of assets | 4,000 | -9,004 |
| Provision for credit losses (recoveries of) | -9,127 | -13,248 |
| Inventory obsolescence expense (recovery) | -43,681 | -95,302 |
| Accounts receivable | -164,190 | 65,150 |
| Prepaid expenses and other assets | 759,594 | -690,010 |
| Inventory | -38,353 | -83,399 |
| Deferred revenue | -300 | 5,000 |
| Income taxes payable | -245,085 | 23,290 |
| Accounts payable, accrued expenses and other liabilities | 19,734 | -3,213,100 |
| Net cash used in operating activities | -5,904,585 | -17,033,044 |
| Purchases of property and equipment | 75,105 | 492,973 |
| Proceeds from maturities of marketable investment securities | 2,252,362 | 31,509,485 |
| Purchases of marketable securities | 2,362 | 6,588,577 |
| Net cash provided by investing activities | 2,174,895 | 24,427,935 |
| Issuance of common stock related to at-the-market offering, net of offering costs | 530,183 | 783,746 |
| Issuance of common stock related to registered direct offering, net of offering costs | 3,528,269 | - |
| Net cash provided by financing activities | 4,058,452 | 783,746 |
| Net increase (decrease) in cash and cash equivalents | 328,762 | 8,178,637 |
| Cash and cash equivalents at end of period | 11,443,943 | - |
Co-Diagnostics, Inc. (CODX)
Co-Diagnostics, Inc. (CODX)